ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,172Medicare Part D Prescriptions Filled, Including Refills

Rank: 39 out of 663

$525K Total Retail Price of All Prescriptions

Rank: 59 out of 663

616 Patients Receiving at Least One Drug in Part D
85%Patients 65 Years and Older
37% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Colorado
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 616 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

10% of this provider’s 616 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

2% of this provider’s 9,770 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Colorado
SIMVASTATIN 633 544 1 1
LEVOTHYROXINE SODIUM 619 558 2 3
LISINOPRIL 398 355 3 2
AMLODIPINE BESYLATE 322 308 4 5
METFORMIN HCL 310 252 5 9
OMEPRAZOLE 304 264 6 4
HYDROCODONE-ACETAMINOPHEN 265 210 S3 7 6
METOPROLOL SUCCINATE 260 219 8 25
TRAMADOL HCL 258 225 9 17
WARFARIN SODIUM 257 225 10 8
FUROSEMIDE 255 209 11 7
METOPROLOL TARTRATE 228 216 12 11
HYDROCHLOROTHIAZIDE 186 175 13 12
LOSARTAN POTASSIUM 182 147 14 14
DONEPEZIL HCL 171 171 15 40
SERTRALINE HCL 166 143 16 35
ATORVASTATIN CALCIUM 161 149 17 13
CITALOPRAM HBR 158 147 18 18
POTASSIUM CHLORIDE 156 130 19 23
ZOLPIDEM TARTRATE 138 109 20 16
TRAZODONE HCL 127 82 21 34
FENTANYL 123 123 S2 22 75
ATENOLOL 116 111 23 10
GABAPENTIN 108 95 24 20
RAMIPRIL 88 80 25 132
CARVEDILOL 88 70 25 47
NAMENDA 83 83 27 57
GLIMEPIRIDE 83 83 27 84
CLOPIDOGREL 82 69 29 65
ALLOPURINOL 82 82 29 28
DIGOXIN 81 80 31 50
CLONIDINE HCL 81 63 31 79
LISINOPRIL-HYDROCHLOROTHIAZIDE 79 65 33 22
ALENDRONATE SODIUM 74 73 34 15
GLIPIZIDE ER 72 59 35 130
CYMBALTA 69 69 36 54
NYSTATIN 68 65 37 124
FLUOXETINE HCL 63 42 38 32
TRIAMTERENE-HCTZ 62 57 39 42
MELOXICAM 60 48 40 61
PRAVASTATIN SODIUM 59 52 41 21
PANTOPRAZOLE SODIUM 59 57 41 45
SYNTHROID 58 57 43 46
POLYETHYLENE GLYCOL 3350 57 56 44 82
CARBIDOPA-LEVODOPA 50 50 45 102
BENAZEPRIL HCL 50 50 45 141
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 1, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.